Janux Therapeutics (JANX) Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Janux Therapeutics (JANX) PT Raised to $115 at Stifel
December 3, 2024 8:22 AM ESTStifel analyst Bradley Canino raised the price target on Janux Therapeutics (NASDAQ: JANX) to $115.00 (from $70.00) while maintaining a Buy rating.
The analyst comments "The JANX007 (PSMA-TRACTr) phase 1 update (LINK) leads us to increase our PoS for 2L and 3L mCRPC to 50% and 65%, respectively... More
William Blair on Janux Therapeutics (JANX): 'Exceeding Investor Expectations and Raising the Bar in mCRPC'
December 3, 2024 7:06 AM ESTWilliam Blair analyst Matt Phipps reiterated an Outperform rating on Janux Therapeutics (NASDAQ: JANX).
The analyst comments "On Monday, December 2, Janux disclosed updated clinical results with JANX007, the companys PSMAxCD3 TRACTr bispecific T-cell engager, in patients with heavily pretreated metastatic castrate resistant prostate cancer (mCRPC), demonstrating... More
Janux Therapeutics (JANX) PT Raised to $91 at Leerink Partners
December 3, 2024 6:55 AM ESTLeerink Partners analyst Jeffrey La Rosa raised the price target on Janux Therapeutics (NASDAQ: JANX) to $91.00 (from $79.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: Janux (JANX, OP) delivered with updated Ph 1 dose escalation data for lead candidate JANX007 (masked PSMA x... More
Stifel Reiterates Buy Rating on Janux Therapeutics (JANX)
December 3, 2024 5:27 AM ESTStifel analyst Bradley Canino reiterated a Buy rating and $70.00 price target on Janux Therapeutics (NASDAQ: JANX).
The analyst comments "Updated ph.1a JANX007 (PSMA-TRACTr) ~5L mCRPC data at therapeutic weekly dose regimens suggest a potentially guaranteed biochemical PSA response pre-Pluvicto, with three-quarters lasting >12wks.... More
Janux Therapeutics (JANX) PT Raised to $100 at BTIG, 'The World Is Not Enough — 007 Strikes Again Exceeding The Street's Highest Expectations'
December 3, 2024 5:26 AM ESTBTIG analyst Justin Zelin raised the price target on Janux Therapeutics (NASDAQ: JANX) to $100.00 (from $82.00) while maintaining a Buy rating.
The analyst comments "Janux surpassed the street's high expectations with their eagerly anticipated data update today (see our preview note here). Heading into the data, we've heard investor concerns that expectations were too high for JANX to meet our bull case scenario of >60% PSA50 at 12-wks,... More
